Unknown

Dataset Information

0

Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses.


ABSTRACT: Adjuvants are critical for improving the quality and magnitude of adaptive immune responses to vaccination. Lipid nanoparticle (LNP)-encapsulated nucleoside-modified mRNA vaccines have shown great efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but the mechanism of action of this vaccine platform is not well-characterized. Using influenza virus and SARS-CoV-2 mRNA and protein subunit vaccines, we demonstrated that our LNP formulation has intrinsic adjuvant activity that promotes induction of strong T follicular helper cell, germinal center B cell, long-lived plasma cell, and memory B cell responses that are associated with durable and protective antibodies in mice. Comparative experiments demonstrated that this LNP formulation outperformed a widely used MF59-like adjuvant, AddaVax. The adjuvant activity of the LNP relies on the ionizable lipid component and on IL-6 cytokine induction but not on MyD88- or MAVS-dependent sensing of LNPs. Our study identified LNPs as a versatile adjuvant that enhances the efficacy of traditional and next-generation vaccine platforms.

SUBMITTER: Alameh MG 

PROVIDER: S-EPMC8566475 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC6082880 | biostudies-literature
| S-EPMC7596866 | biostudies-literature
| S-EPMC8206650 | biostudies-literature
| S-EPMC5987916 | biostudies-literature
| S-EPMC8484368 | biostudies-literature
| S-EPMC8695127 | biostudies-literature
| S-EPMC10869348 | biostudies-literature
| S-EPMC4639468 | biostudies-literature
| S-EPMC9262847 | biostudies-literature
| S-EPMC5858788 | biostudies-literature